Flow cytometric evidence of apoptosis in human pancreatic cancer xenografts treated with Sandostatin (octreotide)

Anticancer Research

Volumn 20, Issue 3 A, 2000, Pages 1663-1666

  Zalatnai, Attila ^a   Szegedi, Zsolt ^a   Bocsi, Jozsef ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

Apoptosis; Human tumors; Octreotide; Pancreatic cancer; Xenograft

Indexed keywords

OCTREOTIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FLOW CYTOMETRY; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOENZYME TECHNIQUES; MICE; NEOPLASM TRANSPLANTATION; OCTREOTIDE; PANCREATIC NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

EID: 0033866848     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Arnold R, Neuhaus C and Benning R: Somatostatin analog sandostatin and inhibition of human growth in patients with metastatic endocrine gastroenteropancreatic tumors. World J Surg 17: 511-519, 1993.
2. Poston GJ, Townsend CM.jr., Rajareman S, Thompson JC and Singh P: Effect of somatostatin and tamoxifen on the growth of human pancreatic cancers in nude mice. Pancreas 5: 151-157, 1990.
3. Weckbecker G, Tolcsvai L, Liu R and Bruns C: Preclinical studies on the anticancer activity of somatostatin analogue octreotide (SMS 201-995). Digestion 54: (Suppl. 1), 98-103, 1993.
4. Ebert M, Friess H, Beger HG and Büchler MW: Role of octreotide in the treatment of pancreatic cancer. Digestion 55: (Suppl 1), 48-51, 1994.
5. Rosenberg L, Barkun AN, Denis MH and Pollak M: Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. Cancer 75: 23-28, 1995.
6. Sulkowski U, Dinse P, Haus U and Collins W: Regression of a distal bile duct carcinoma after treatment with octreotide for 6 months. Digestion 58: 407-409, 1997.
7. Weckbecker G, Raulf F, Bodmer D and Bruns C: Indirect antiproliferative effect of the somatostatin analog octreotide on M1APaCa-2 human pancreatic carcinoma in nude mice. Yale J Biol Med 70: 549-554, 1997.
8. Pollak MN and Schally AV: Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med 217: 143-152, 1998.
9. Reubi C, Horisberger U, Essed CE Jeckel J, KJijn JG and Lamberts SW: Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas. Gastroenterology 95: 760-763, 1988.
10. Singh P Townsend CM jr., Poston GJ and Reubi JC: Specific binding of cholecystokinin, estradiol and somatostatin to human pancreatic cancer xenografts. J Steroid Biochem Mol Biol 39: 759-767, 1991.
11. Gillespie J, Poston GJ, Schachter M and Guillou PJ: Human pancreatic cancer cell lines do not express receptors for somatostatin. Br J Cancer 66: 483-487, 1992.
12. Fekete M, Zalatnai A, Comaru-Schally AM and Schally AV: Membrane receptors for peptides in experimental and human pancreatic cancers. Pancreas 4: 521-528, 1989.
13. Vidai C, Rauly I, Zeggari M, Delesque N, Esteve JP, Saint-Laurent N, Vaysse N and Susini C: Up-regulation of somatostatin receptors by epidermal growth factor and gastrin in pancreatic cancer cells. Mol Pharmacol 46: 97-104, 1994.
14. Qin Y, Ertl T, Groot K Horvath J, Cai RZ and Schally AV: Somatostatin analog RC-160 inhibits growth of CFPAC-I human pancreatic cancer cells in vitro and intracellular proliferation of cyclic adenosine monophosphate. Int J Cancer 60: 694-700, 1995.
15. Tang C, Biemond I, Verspaget HW, Offerhaus GJ and Lamers CB: Expression of somatostatin receptors in human pancreatic tumor. Pancreas 17: 80-84, 1998.
16. Fisher WE, Doran TA, Muscarella II P, Boros LG, Ellison EC and Schirmer WJ: Expression of somatostatin receptor subtype 1-5 genes in human pancreatic cancer. J Natl Cancer Inst 90: 322-324, 1998.
17. Douziech N, Calvo E, Coulombe Z, Muradia G, Bastien J, Aubin RA, Lajas A and Morisset J: Inhibitory and stimulatory effect of somatostatin on two human pancreatic cancer cell lines: a primary role for tyrosine phosphatase SHP-1. Endocrinology 140: 765-777, 1999.
18. Soini Y, Pääkkö P and Lehto V-P: Histopathological evaluation of apoptosis in cancer. Am J Pathol 153: 1041-1053, 1998.
19. Kong J and Ringer DP: Quantitative in situ image analysis of apoptosis in well and poorly differentiated tumors from rat liver. Am J Pathol 147: 1626-1632, 1995.
20. Telford WG, King LE and Fraker PJ: Evaluation of glucocorticoid-induced DNA fragmentation in mouse thymocytes by flow cytometry. Cell Prolif 24: 447-459, 1991.
21. Zalatnai A, Bocsi J, Timar F and Babo I: Establishment and characterization of a new transplantable pancreatic cancer xenograft (PZX-5) in immunosuppressed mice. Int J Pancreatol 23: 51-62, 1998.
22. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F and Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Meth 139: 271-279, 1991.
23. Pagliacci MC, Tognellini R, Grignani F and Nicoletti I: Inhibition of human breast cancer cells (MCF-7) growth in vitro by the somatostatin analog SMS 201-995: effects on cell cycle parameters and apoptotic cell death. Endocrinology 129: 1555-2562, 1991.
24. Sharma K and Srikant CB: Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells. Int J Cancer 76: 259-266, 1998.
25. Melen-Mucha G. Winczyk K and Pawlikowski M: Somatostatin analogue octreotide and melatonin inhibit bromodcoxyuridine incorporation into cell nuclei and enhance apoptosis in the transplantable murine colon 38 cancer. Anticancer Res 18: 3615-3619, 1988.
26. Iman H, Eriksson B, Lukinius A, Janson ET, Lindgren PG, Wilander E and Oberg K: Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs. Acta Oncol 36: 607-614, 1997.
27. Szende B, Zalatnai A and Schally AV: Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin. Proc Natl Acad Sci USA 86: 1643-1647, 1989.
28. Szende B, Srkalovic G, Schally AV, Lapis K and Groot K: Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancers in hamsters. Events that accompany tumor regression. Cancer 65: 2279-2290, 1990.
29. Szepeshazi K, Lapis K and Schally AV: Effect of combination treatment with analogs of luteinizing hormone-releasing hormone (LH-RH) or somatostatin and 5-fluorouracil on pancreatic cancer in hamsters. Int J Cancer 49: 260-266, 1991.
30. Ungeforen H, Voss M, Jansen M, Roeder C, Henne-Bruns D, Kremer B and Kalthoff H: Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res 58: 1741-1749, 1998.
31. Srikant CB: Cell cycle dependent induction of apoptosis by somatostatin analog SMS 201-995 in AtT-20 mouse pituitary cells. Biochem Biophys Res Commun 209: 400-406, 1995.
32. Virkajarni N, Pääkkö P and Soini Y: Apoptotic index and apoptosis influencing proteins bcl-2, mcl-1, bax and caspases 3, 6 and 8 in pancreatic carcinoma. Histopathology 33: 432-439, 1998.
33. Lee JU, Hosotani R, Wada M, Doi R, Kosiba T, Fujimoto K, Miyamoto Y, Mori C, Nakamura N, Shiota K and Imamura M: Mechanism of apoptosis induced by cisplatin and VP-16 in PANC-1 cells. Anticancer Res 17: 3445-3450, 1997.
34. Hawkins RA, Sangster K and Arends MJ: Apoptotic death of pancreatic cancer cells induced by polyunsaturated fatty acids varies with 12 double bound number and involves and oxidative mechanism J Pathol 185: 61-70, 1998.
35. El-Metwally TH and Adrian TE: Optimization of treatment conditions for studying the anticancer effects of retinoids using pancreatic adenocarcinoma as a model. Biochem Biophys Res Comm 257: 596-603, 1999.
36. Bouvet M, Bold RJ, Lee J, Evans DB, Abbruzzese JL, Chiao PJ, McConkey DJ, Chandra J, Chada S, Fang B and Roth JA: Adenovirus-mediated wild-type p53 suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer. Ann Surg Oncol 5: 681-688, 1998.
37. Weckbecker G, Raulf F, Tolcsvai L and Bruns C: Potentiation of the anti-proliferative effects of anti-cancer drugs by octreotide in vitro and in vivo. Digestion 57: (Suppl. 1), 22-28, 1996.